Geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation

Geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest story, Nov 5, 2026: “Tailored transplant care in older adults shows promise”.

Intervention

1 paper studies it2 findingsUpdated Nov 5, 2026

1 new paper in 30 daysSee all 1 papers on geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation

At a glance

The findings reach people, from one lab or study. 1 lab.

“The study met the primary endpoint with one-year NRM of 6.3% with no unexpected toxicities attributable to the intervention.”

Prospective study of longitudinal geriatric assessment with risk-adapted interventions for older patients in allogeneic hematopoietic cell transplantationHaematologica2026doi:10.3324/haematol.2026.301206

None of its findings points the other way.

1 lab

Human trial1

What is geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation linked with?

Studies link geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation with 2 measures, most often patient-reported and objective functioning (1 study) and one-year non-relapse mortality (1).

Patient-reported and objective functioning

mixedin humans1

1 study

Geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation is associated with patient-reported and objective functioning in humans (First allogeneic hematopoietic cell transplantation) (Stable to improved).
“Both patient reported and objective functioning outcomes were stable to improved by 6 to 12 months after alloHCT.”
Human trialFirst allogeneic hematopoietic cell transplantation6 to 12 months after transplantationn = 32
Tailored transplant care in older adults shows promise
HaematologicaNov 5, 2026

One-year non-relapse mortality

downin humans1

1 study

Geriatric assessment-guided risk-adapted allogeneic hematopoietic cell transplantation is associated with one-year non-relapse mortality in humans (First allogeneic hematopoietic cell transplantation; historical mortality rates of 25%) (One-year non-relapse mortality 6.3%; historical rates 25%).
“The study met the primary endpoint with one-year NRM of 6.3% with no unexpected toxicities attributable to the intervention.”
Human trialFirst allogeneic hematopoietic cell transplantation; historical mortality rates of 25%One yearn = 32
Tailored transplant care in older adults shows promise
HaematologicaNov 5, 2026

Latest

1 paper in 12 months

HaematologicaNov 5

Tailored transplant care in older adults shows promise

Deaths unrelated to disease relapse reached 6.3% at one year, compared with historical rates of 25%, in 32 patients aged 60 or older.Deaths unrelated to disease relapse reached 6.3% at one year, compared with historical rates of 25%, in 32 patients aged 60 or older.

Single-arm trial · 32 peopleInterventions

Paper